Methods for treatment of cardiovascular disorders and diseases

Abstract

Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

1 . A method for reducing apoptosis resulting from a cardiovascular disorder, disease or condition, selected from the group consisting of congestive heart failure, cardiac hypertrophy including atrial and ventricular hypertrophy, myocardial ischemia, myocardial ischemia and reperfusion injury, cardiomyopathies, and arrhythmias in a subject in need thereof, said method comprising administering to the subject an effective amount of S(−)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein said S(−)—N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is S(−)—N-propargyl-1-aminoindan. 
     
     
         3 . The method of  claim 1 , wherein said S(−)—N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of S(−)—N-propargyl-1-aminoindan. 
     
     
         4 . The method of  claim 3 , wherein said pharmaceutically acceptable salt is selected from the group consisting of the mesylate salt; the esylate salt; the sulfate salt; the hydrochloride salt; the maleate salt; the fumarate salt, the tartrate salt; the hydrobromide salt; the p-toluenesulfonate salt; the benzoate salt; the acetate salt; and the phosphate salt of S(−)—N-propargyl-1-aminoindan. 
     
     
         5 . A method for reducing apoptosis and cardiac myocyte cell death following onset and as a result of congestive heart failure, cardiac hypertrophy including atrial and ventricular hypertrophy, myocardial ischemia, myocardial ischemia and reperfusion injury, cardiomyopathies, and arrhythmias in a patient in need thereof, said method comprising administering to the subject an effective amount of S(−)—N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 5 , wherein said S(−)—N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is S(−)—N-propargyl-1-aminoindan. 
     
     
         7 . The method of  claim 5 , wherein said S(−)—N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of S(−)—N-propargyl-1-aminoindan. 
     
     
         8 . The method of  claim 7 , wherein said pharmaceutically acceptable salt is selected from the group consisting of the mesylate salt; the esylate salt; the sulfate salt; the hydrochloride salt; the maleate salt; the fumarate salt, the tartrate salt; the hydrobromide salt; the p-toluenesulfonate salt; the benzoate salt; the acetate salt; and the phosphate salt of S(−)—N-propargyl-1-aminoindan.